Discovery ADMET and In Vitro Metabolism

SRI is a leader in the development and application of in vitro models for ADMET evaluations (ADMET: Absorption, Distribution, Metabolism, Excretion, and Toxicity). Obtaining data on potential toxicity early in the development process can help you make informed decisions to move promising leads forward and exclude liabilities.

Our staff has extensive experience in elucidating tissue-specific mechanisms of toxicity for various species and organs. We pioneered the application of human tissue preparations to predicting interspecies differences in drug metabolism, potential drug interactions, and human drug metabolizing enzymes.

Related Services

Predictive ADMET

  • Membrane permeability: PAMPA, Caco-2, MDCK cells

  • Metabolic stability: liver or small intestine microsomes

  • Plasma stability

  • Cytochrome P450 (CYP) inhibition

  • Plasma protein binding

  • p-Glycoprotein substrate assays

  • In vivo pharmacokinetic screens

  • High-throughput LC-MS/MS quantitation

  • First in vivo dose to mice

In Vitro Metabolism and Toxicity

  • Metabolite profiling and identification

  • Reaction phenotyping: CYP, UGT, SULT

  • Drug-drug interactions

  • Peroxisome proliferation

  • Co-incubation screens

  • Therapeutic index estimations

  • Cytotoxicity and hepatotoxicity screening

  • Mini-Ames mutagenicity screen

  • Mini I (hERG) cardiotox liability screen (offered through agreement with ChanTest Corporation)

Projects

bioscience workers in a lab

SRI is conducting preclinical development of treatments for diseases such as tuberculosis, West Nile virus, hepatitis, and biodefense pathogens and toxins.

scientist looking through a microscope

For the National Institute of Mental Health (NIMH), SRI performs preclinical safety and pharmacokinetics studies for brain imaging agents and drugs to treat mental illnesses.

SRI In the News

Jon Mirsalis
Fighting the War on Infectious Diseases: An Interview with SRI's Jon Mirsalis

Jon Mirsalis of SRI Biosciences describes how SRI researchers are developing drugs to fight infectious diseases like HIV, malaria, tuberculosis and the flu. Over the years, SRI has helped save thousands of lives by moving drugs from the early discovery stage into human clinical trials.